Diabetes Drug Therapy Market 2021 : GCC Industry Growth, Opportunities, Industry Analysis and Forecasts 2027

 Infinium Global Research’s recent report on the “GCC Diabetes Drug Therapy Market (By Service Type (Insulin, Biguanides, Meglitinides, Sulfonylureas, Inhibitors, And Others), By Applications (Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes)): Industry Analysis, Trends, Size, Share and Forecasts up to 2027” provides a comprehensive outline of the factors responsible for the growth of the market.

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/gcc/sample-request/21

"We are Now Including the Impact Analysis of COVID-19 on this Premium Report and the Forecast Period of this Report shall be Revised to 2023-2030." 

The Section on the Impact of COVID-19 on this Market is Included in the Report for Free.

The Arabian Gulf countries have experienced a rapid rise in the prevalence of diabetes over the past decade. The rising global demand for diabetes management options has encouraged the development of several new diabetes medications, drug-device mixtures, and drug-device-diagnostic combinations intended to advance patient care and provide salient benefits to patients.

The COVID-19 pandemic has created a stressful mind among people having chronic disease such as diabetes connected to medicines and diagnostic tools. COVID-19 is likely to infect people having diabetes with a 50% higher risk as compared to those who do not have diabetes. The hospitals gave preference to COVID-19 cases over patients with other less-severe health conditions. Thus, the number of procedures performed on diabetes health conditions fell rapidly during the pandemic. However, COVID-19 is expected to be an opportunity for the diabetes drug therapy market, as patients having diabetes are at a higher risk of getting COVID-19 infection.  

The Insulin Segment to Dominate the Diabetes Drug Therapy Market

Based on the product, the diabetes drug therapy market is categorized into Insulin, Biguanides, Meglitinides, Sulfonylureas, Inhibitors, and others. Among these, the Insulin segment is expected to dominate the diabetes drug therapy market. The factors such as the increasing use of insulin to control the glucose level in blood by type 1 diabetes patients, rising market demand for human insulin analogs, and favorable medical reimbursements are driving the demand for the Insulin segment. Globally, Insulin has been used in the treatment of diabetes for over 90 years.

Need Assistance? Send an Enquiry@ https://www.infiniumglobalresearch.com/gcc/customization/21  

Saudi Arabia to Be the Dominant Country in GCC Diabetes Drug Therapy Market

Among the geographies, the GCC diabetes drug therapy market is segmented into Saudi Arabia, Kuwait, UAE, Qatar, Bahrain, and Oman. Saudi Arabia accounted for the majority of the market share of the GCC diabetes drug therapy market in 2020 and is anticipated to remain dominant throughout the forecast period.  According to the World Health Organization (WHO), Saudi Arabia ranks seventh in the world for the rate of diabetes, and second highest in the Middle East. It is estimated that around 7 million of the population are diabetic in the country and nearly 3 million have pre-diabetes. The factors such as consequences of lifestyle as lack of exercise, unhealthy diet, obesity, and overweight are driving the diabetes drug therapy market in Saudi Arabia.

Companies Operating in Diabetes Drug Therapy Market are Focusing on Partnerships and Product Innovations

The GCC diabetes drug therapy market includes several established global players as well as local players. Some of the leading players present in the market are Becton Dickinson, AstraZeneca, F. Hoffmann-La Roche AG, Medtronic plc, DexCom, Inc., and Abbott Laboratories among others. Recently, AstraZeneca has come into partnership with UK medtech start-up Gendius, which specializes in remote disease management. The company has launched the GCC Health Innovation Hub, which is a culmination of digital innovation efforts to make diagnosis and treatment easier for diabetic patients. An artificial intelligence (AI)-powered platform and app are known as HealthGATE will be launched later to support diabetic patient care in the GCC. Furthermore, in April 2021, Researchers at New York University Abu Dhabi developed a new oral delivery system for insulin that could replace the traditional injection used by diabetes patients.

More Insights on This Report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/gcc/enquiry/21

Reasons to Buy this Report:

=> Comprehensive analysis of regional markets of the GCC diabetes drug therapy.

=> Complete coverage of all the product types and application segments to analyze the trends, developments, and market size forecast up to 2027.

=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company. 

 => Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand and/or diversify.